Why Periodic Safety Reports matter

Once a medicinal product is on the market, initial clinical-trial data no longer suffice to fully characterise its safety. Real-world use may reveal rare, delayed, or population-specific adverse reactions. Periodic Safety Update Reports (PSURs) — or their globally harmonised counterpart, Periodic Benefit-Risk Evaluation Reports (PBRERs) — are the cornerstone of post-marketing pharmacovigilance. They enable the marketing-authorisation holder (MAH) to re-evaluate the risk-benefit balance of a medicine, summarise all safety data collected during the reporting period, and support regulatory decisions such as labelling updates, risk minimisation measures, or, in extreme cases, withdrawal.

For companies operating internationally or across regions (e.g. Europe and Africa), a robust PSUR/PBRER process ensures compliance with global standards while safeguarding public health.

Global (International / EU / ICH) Requirements

Structure, Content and Submission

• Global best practice is defined by guidelines such as European Medicines Agency (EMA)’s rules and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline E2C(R2), which set out the format and content of PSURs / PBRERs.
• The report should include a critical, cumulative and up-to-date analysis of all available safety data (clinical studies, spontaneous/adverse event reports, literature, usage data, observational studies, registries, etc.) during the interval.
• It must summarise product information (brand, dosage forms, strength, manufacturer, countries where marketed), surveillance period, number and nature of ADRs/serious adverse events (local and foreign), safety signal evaluations, benefit-risk assessment, and, where relevant, data on efficacy failures or lack of expected effect.

Submission Timing & Cycle

• The submission frequency may vary depending on the active substance/product: often more frequent in the early post-authorisation years (e.g. every 6 months), then annually, and later possibly every 2–3 years, depending on risk profile, regulatory requirements or updates in safety data.
• In the EU context, many active substances are listed in a maintained reference list (e.g. the “EURD list”), which defines data-lock points (DLPs) and submission schedules for PSURs across all member states.
• For MAHs holding products in multiple countries, a single PSUR can — and often should — cover all products containing the same active substance, across different indications/routes, as long as the report includes all relevant data globally.

Purpose & Outcomes

• The PSUR/PBRER is not just a list of adverse events — it is a critical, standalone scientific assessment of the benefit-risk balance of the product, in light of up-to-date real-world data.
• Based on PSUR evaluation, regulatory authorities may require updates to product information (e.g. warnings, contraindications), impose risk minimisation measures, request additional studies, or in rare cases withdraw or suspend the product.

Requirements and Current Status in Tanzania / East Africa

Regulatory Framework

• In Tanzania, the regulatory agency Tanzania Medicines and Medical Devices Authority (TMDA) requires marketing authorisation holders to fulfil ongoing pharmacovigilance obligations. Its guidelines explicitly mention “Safety Update Reports (PSURs)” as part of post-marketing requirements.
• For medical devices (and diagnostics), TMDA also expects vigilance and post-marketing surveillance, including reporting of adverse events or incidents, though the PSUR concept may apply differently in that context.

Evolving Pharmacovigilance Infrastructure — e.g. AU-3S / Regional Integration

• Tanzania contributes to the regional safety-data system of AU-3S Project, which aims to pool pharmacovigilance reports across several African countries, enabling better signal detection and real-time safety surveillance.
• TMDA’s ongoing pharmacovigilance strengthening project (2024–2026) includes as deliverables the assessment of PSURs submitted by MAHs, training of PV focal persons, and system improvements for regional PV centres.

What this means for local MAHs / Suppliers

• Companies marketing products in Tanzania or East Africa must ensure they have robust safety-data collection mechanisms (spontaneous ADR reports, literature monitoring, periodic data aggregation) to support PSUR submission.
• They must be ready to compile and submit PSURs (or equivalent safety update reports) in compliance with both local requirements (as per TMDA guidelines) and — if they also export or hold registrations elsewhere — global standards (ICH, EU, etc.).
• Given regional PV harmonisation (e.g. via AU-3S), data from other African countries where the product is marketed may need to be included in PSURs or safety documentation, meaning cross-country coordination is necessary.

Challenges for MAHs and the Role of Alcare Consultancy

Meeting global and regional PSUR requirements can be challenging — especially for companies operating in or exporting to multiple regions, or in contexts where PV infrastructure is still evolving. Some of the typical challenges:

• Setting up and maintaining efficient ADR reporting systems in markets with limited infrastructure (paper-based vs electronic; under-reporting by HCPs and patients)
• Aggregating safety data across multiple countries (domestic, regional, international)
• Ensuring quality and completeness of data to support robust benefit-risk analysis
• Preparing PSURs in proper format consistent with ICH/EU guidelines — which often require expertise in regulatory writing, knowledge of eCTD submission formats, and capability to interpret global and local safety data together
• Aligning submission schedules across different regulatory jurisdictions

This is where Alcare Consultancy can add value:

• We can design and implement a full pharmacovigilance system tailored to your needs — including ADR collection mechanisms (paper-based and/or electronic), signal detection workflows, data management, and safety-data aggregation across markets.
• We help compile and write PSURs / PBRERs in compliance with global standards (ICH, EMA, etc.) while ensuring the format meets local regulatory expectations under TMDA or other national authorities.
• For products marketed in multiple jurisdictions (e.g. EU, Tanzania, other African countries), we provide coordinated global safety data integration — combining foreign literatures, global ADR reports, real-world data, and local reports — to support a comprehensive benefit-risk evaluation.
• We can assist with submission logistics: preparation of dossiers, regulatory filings, and follow-up with authorities; ensuring you meet deadlines and maintain compliance under different regulatory regimes.
• We also support capacity building: training your staff on PV procedures, building local expertise, establishing documentation/manuals (SOPs), and helping navigate regional PV developments (e.g. AU-3S).

Practical Advice / Recommendations for Companies in Tanzania / East Africa

1. Start building your pharmacovigilance system early — even before first ADR reports come in. A well-designed PV system makes PSUR preparation much easier when the time comes.
2. Use both local data (from users, HCPs, patients) and global safety data (foreign ADRs, literature, registries) to get a complete picture of risk across all markets.
3. Maintain good documentation (case reports, safety data logs, usage data, literature reviews, manufacturing info) to support the PSUR analysis.
4. Consider outsourcing or partnering with specialist PV consultancies (like Alcare) if you lack internal capacity — especially for global products or exports.
5. Stay updated with regulatory changes both globally (ICH, EMA, FDA) and locally (TMDA guidelines, regional PV initiatives like AU-3S) to ensure compliance.

Conclusion

Periodic Safety Update Reports (PSURs / PBRERs) are vital instruments for ensuring ongoing safety and effectiveness of medicines after they reach the market. For companies operating in Tanzania, East Africa, or globally — meeting both local regulatory expectations and international PV standards may be complex.

This is exactly where Alcare Consultancy can help: by building robust pharmacovigilance systems, consolidating global and local safety data, preparing high-quality PSUR/PBRER dossiers, submitting them to the right authorities on time, and ensuring your products remain compliant — helping you meet both public health responsibilities and regulatory obligations with confidence.

What is the PSMF — and why it matters

The PSMF is a comprehensive, organized documentation of a company’s pharmacovigilance (PV) system. It describes how the marketing authorisation holder (MAH) collects, manages and reports safety data for its medicinal products, and how the PV-system is structured and operated. 

The PSMF is not part of the marketing authorisation dossier itself — but an independent, living document that must be maintained throughout the product lifecycle. 

For regulatory authorities, the PSMF serves as a “window” into the MAH’s PV system: when authorities perform inspections or audits, they rely on the PSMF to assess whether PV obligations (data collection, reporting, risk-management, quality management, etc.) are met.

For the MAH and its PV team — including the appointed qualified person — the PSMF helps to:

• define and document all PV processes (data collection, processing, reporting, signal detection, risk-management, etc.);
• map out the organisational structure (who does what — e.g. in-house PV staff, external partners, distributors, CROs) and clarify responsibilities;
• provide transparency and traceability on data sources, procedures, quality assurance systems, and compliance efforts;
• aid internal audits and prepare for external inspections (regulatory, for-cause, or routine), by ensuring all relevant information is up-to-date and accessible.

In short — the PSMF is foundational for legitimate, sustainable pharmacovigilance.

Global Regulatory Expectations (e.g., EU, International Standards)

Globally — especially under the regulatory framework of the European Medicines Agency (EMA) and the EU — the PSMF is a mandatory requirement for any MAH with authorised medicinal products.

Some key global requirements / best practices:

• The PSMF must be maintained continuously and reflect the current status of the PV system. If there are changes (personnel, processes, delegated partners, systems), the PSMF must be updated accordingly.
• It must be accessible “on demand”: regulators may request it at any time; within EU, it must be provided within a limited timeframe (commonly 7 days) upon request.
• Its structure typically mirrors guidance from the EU’s “Good Pharmacovigilance Practices (GVP) — Module II”. Common sections/modules include: QPPV information, company organisational structure, sources of safety data, PV processes and procedures, PV quality management system, computerized systems/database, performance metrics, annexes (e.g. list of products, contracts, SOPs, audit reports, responsibilities, delegated partners).
• If the MAH delegates some PV activities (e.g. to local affiliates, distributors, CROs, external service providers), the PSMF must clearly describe these relationships, delineate which PV tasks are delegated, and retain evidence (agreements, contracts, SOPs).
• A reference number or identifier of the PSMF (when applicable) must be assigned uniquely (especially in systems like the EU’s xEVMPD) and communicated if required.

These globally accepted practices ensure that the PV system is robust, transparent, and audit-ready.

PSMF Requirements in Tanzania / East Africa — What Regulations Say

In Tanzania (and more broadly in East Africa under the regional regulatory cooperation framework), there is recognition that PSMF is essential. The Tanzania Medicines and Medical Devices Authority (TMDA), as well as the regional/national pharmacovigilance framework, require MAHs to maintain a PSMF and make it available for inspection.

Some specific points under Tanzanian / East African context:

• The PSMF must be located either at the site where the main PV activities are conducted, or at the site where the responsible QPPV operates.
• It must be continuously accessible (immediately available) — including in electronic form, provided the data are directly accessible at the site where the PSMF is kept.
• Inspections by TMDA (and possibly regional National Medicines Regulatory Authorities — NMRAs) may cover both “system-level” (i.e. PV system operations) and “product-level”. They examine aspects such as collection and archiving of Individual Case Safety Reports (ICSRs), completeness and accuracy, timeliness of submissions (e.g., safety reports, PSURs), quality/performance of the PV system, and compliance with risk-management obligations.
• The PSMF must reflect real, functional PV operations (not just theoretical processes) — meaning documented procedures/SOPs, trained personnel, reporting systems, data management, quality control, audit records, etc.

Moreover, as part of regional harmonization efforts, East-African guidelines echo many of the global best practices for PSMF — including the need to cover global, regional and local safety data for all products marketed in the region.

Given these requirements, a PSMF for Tanzania/East Africa must not only meet international standards (as in EU or other mature regulatory jurisdictions) — but also be adapted to local contexts: local PV reporting processes, local contact persons, local storage and access mechanisms, readiness for national inspections, and compliance with local legislation (e.g. national PV guidelines, national safety-reporting obligations, language/communication with TMDA).

Challenges and Common Pitfalls for MAHs in Tanzania/East Africa

In working toward compliant and robust PSMF systems in Tanzania / East Africa (or other developing markets), MAHs often face several practical challenges:

• Lack of local PV infrastructure / trained personnel: many companies may lack a resident, qualified PV officer or QPPV familiar with local regulatory expectations.
• Delegation without oversight: where PV activities are delegated (e.g., to distributors, local partners, CROs), sometimes the responsibility for documentation and reporting remains unclear — PSMF may not clearly show who does what.
• Inadequate or outdated documentation: PSMF and associated SOPs may be drafted, but not maintained or updated — meaning real practices diverge from documented ones.
• Poor data management: for example, delays or gaps in ICSR collection, assessment, archiving; lack of electronic systems or poor validation/back-up; difficulty in retrieving safety data when needed.
• Inspection unpreparedness: when regulators (e.g. TMDA) request the PSMF or conduct inspections (routine, for-cause, retrospective), some MAHs may struggle to provide up-to-date documentation, leading to non-compliance findings.
• Global vs local data integration: many MAHs operate globally, but collecting and harmonizing safety data from different regions (including local African context) into a unified, consistent PSMF structure can be challenging.

These challenges can expose MAHs to regulatory risk, delays in product registration or renewals, safety-reporting failures, and reputational harm.

How Alcare Consultancy Supports Clients with PSMF: Your PV-Backbone Partner

Given all of the above, a structured, professional approach is critical. That is where Alcare Consultancy — with experience in registration, distribution, storage, and pharmacovigilance for medical products in Tanzania — can provide substantial value. Here’s how Alcare helps clients with PSMF and PV readiness:

• PSMF Development & Implementation: We help write or design a compliant PSMF tailored to your product portfolio — whether you intend to market locally (Tanzania/East Africa) or regionally/global. We map out organisational structure, data-flow, PV responsibilities (local & global), sources of safety data, and integrate SOPs.
• Local Adaptation: We ensure the PSMF meets both global (e.g. GVP-based) standards and local regulatory requirements (TMDA / East Africa PV guidelines), including defining roles of local PV contact persons, specifying PSMF location, access, and language/format appropriate for local inspections and regulatory communication.
• PV System Setup / Delegation Oversight: For companies that outsource or delegate PV tasks (e.g. to distributors, local partners, or CROs), Alcare can help draft appropriate PV-agreements, clarify scopes, and ensure the PSMF reflects these arrangements — reducing compliance risk.
• SOP Development & Quality Management: We assist in developing Standard Operating Procedures (SOPs) for all PV processes (ICSR collection & follow-up, safety reporting, signal detection, PSUR preparation, archiving, audits). We also help integrate PV within broader quality systems (e.g. GMP, distribution, storage) — essential for companies like yours that supply, distribute or store products.
• Inspection Readiness & Audit Support: Alcare helps prepare clients for regulatory inspections (by TMDA or other NMRAs) — reviewing PSMF, ensuring documents are up-to-date, data management is compliant, SOPs are in place, and personnel are trained. We can even conduct “ready-made internal audits” to identify and remediate gaps before formal inspection.
• Ongoing Maintenance & Updates: Since products, distribution networks and partners evolve, Alcare offers periodic review and updates of the PSMF and associated PV documentation — ensuring the system remains current and compliant as business grows or changes.

Through these services, Alcare Consultancy becomes a strategic partner — transforming PV from a compliance burden into a structured, sustainable asset that supports product safety, regulatory compliance, and business continuity.

Why PSMF Should Be a Priority for MAHs in Tanzania / East Africa

• Because authorities (e.g. TMDA) require access to PSMF for inspections — inadequate or missing PSMF can lead to non-compliance, regulatory sanctions, or delays in registration/renewal.
• Because maintaining PSMF ensures transparency and consistency in safety-data handling, which is critical for patient safety, risk management, and credibility among healthcare professionals and regulators.
• Because as markets grow, distributions expand, and collaborations increase (imports, local partners, exports), a robust PSMF helps integrate global and local safety data, manage delegated PV responsibilities, and safeguard operations long-term.
• Because having a professional PV infrastructure (documented, audit-ready, transparent) gives companies (especially small/medium enterprises) leverage, confidence, and readiness — reducing risk of inspection failures.

Conclusion

The Pharmacovigilance System Master File (PSMF) is the cornerstone of any robust pharmacovigilance system. While global regulatory frameworks (such as those of the EU) define its structure and mandate its maintenance, local regulators in Tanzania and East Africa (e.g. TMDA) have integrated PSMF requirements into national PV regulations — reflecting a growing commitment to drug safety, quality, and compliance.

For MAHs — especially those operating in multiple markets or supplying/importing products into Tanzania — building, maintaining and regularly updating a PSMF is not optional, but essential.

With Alcare Consultancy’s expertise in PV, regulatory compliance, distribution, and local knowledge, we are well-positioned to support companies in creating a PSMF that meets global standards and local requirements — ensuring your operations are compliant, audit-ready, and built on a solid PV foundation.